Andrew J Plodkowski
Overview
Explore the profile of Andrew J Plodkowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
2931
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomez-Banoy N, Ortiz E, Jiang C, Dagher C, Sevilla C, Girshman J, et al.
J Clin Invest
. 2024 Jun;
134(17).
PMID: 38900575
BACKGROUNDObesity is the foremost risk factor in the development of endometrial cancer (EC). However, the impact of obesity on the response to immune checkpoint inhibitors (ICI) in EC remains poorly...
2.
Memon D, Schoenfeld A, Ye D, Fromm G, Rizvi H, Zhang X, et al.
Cancer Cell
. 2024 Jan;
42(2):209-224.e9.
PMID: 38215748
Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired...
3.
Blow T, Murthy A, Grover R, Schwitzer E, Nanus D, Halpenny D, et al.
Eur Urol Open Sci
. 2023 Nov;
57:1-7.
PMID: 38020528
Background: Androgen deprivation therapy (ADT) is a common treatment modality for men with prostate cancer. Increases in adipose tissue mass and decreases in skeletal muscle mass are known on-target adverse...
4.
Thummalapalli R, Ricciuti B, Bandlamudi C, Muldoon D, Rizvi H, Elkrief A, et al.
Clin Cancer Res
. 2023 Jul;
29(21):4408-4418.
PMID: 37432985
Purpose: We sought to identify features of patients with advanced non-small cell lung cancer (NSCLC) who achieve long-term response (LTR) to immune checkpoint inhibitors (ICI), and how these might differ...
5.
Pai J, Hellmann M, Sauter J, Mattar M, Rizvi H, Woo H, et al.
Cancer Cell
. 2023 Mar;
41(4):776-790.e7.
PMID: 37001526
Paired single-cell RNA and T cell receptor sequencing (scRNA/TCR-seq) has allowed for enhanced resolution of clonal T cell dynamics in cancer. Here, we report a scRNA/TCR-seq analysis of 187,650 T ...
6.
Elkrief A, Makhnin A, Moses K, Ahn L, Preeshagul I, Iqbal A, et al.
Clin Cancer Res
. 2023 Feb;
29(8):1423-1428.
PMID: 36729110
Purpose: Primary and acquired resistance to osimertinib remain significant challenges for patients with EGFR-mutant lung cancers. Acquired EGFR alterations such as EGFR T790M or C797S mediate resistance to EGFR tyrosine...
7.
Schoenfeld A, Rizvi H, Memon D, Shaverdian N, Bott M, Sauter J, et al.
Clin Cancer Res
. 2022 Jun;
28(17):3797-3803.
PMID: 35767426
Purpose: Clinical patterns and the associated optimal management of acquired resistance to PD-(L)1 blockade are poorly understood. Experimental Design: All cases of metastatic lung cancer treated with PD-(L)1 blockade at...
8.
Ricciuti B, Wang X, Alessi J, Rizvi H, Mahadevan N, Li Y, et al.
JAMA Oncol
. 2022 Jun;
8(8):1160-1168.
PMID: 35708671
Importance: Although tumor mutation burden (TMB) has been explored as a potential biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about the optimal TMB...
9.
Murciano-Goroff Y, Pak T, Mondaca S, Flynn J, Montecalvo J, Rekhtman N, et al.
Br J Cancer
. 2021 Dec;
126(6):889-898.
PMID: 34963703
Background: While 2-4% of lung cancers possess alterations in BRAF, little is known about the immune responsiveness of these tumours. Methods: Clinical and genomic data were collected from 5945 patients...
10.
Ricciuti B, Arbour K, Lin J, Vajdi A, Vokes N, Hong L, et al.
J Thorac Oncol
. 2021 Nov;
17(3):399-410.
PMID: 34740862
Introduction: STK11 and KEAP1 mutations (STK11 mutant [STK11] and KEAP1) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 has been associated with resistance to programmed...